A bipartisan group of senators are asking the US FDA to make it easier for sponsors to develop generic versions of insulins even as the agency transitions regulation of the products from the NDA to BLA framework.
Senators Press US FDA For Faster Approval Of Generic Insulin
Bipartisan group wants more flexibility for pending applications during NDA-to-BLA transition; Lilly's authorized generic of Humalog suggests political pressure on insulin pricing is having an impact.
More from Pricing Debate
More from Market Access
• By
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
• By
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.
• By
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.